American Assets Trust is a self-administered real estate investment trust that owns, operates, acquires and develops retail, office, multifamily and mixed-use properties in Southern California, Northern California, Oregon, Washington, Texas and Hawaii. The company operates in four segments: Retail, which primarily include rental of retail space and other tenant services, including tenant reimbursements, parking and storage space rental; Office, which primarily include rental of office space and other tenant services; Multifamily, which include rental of apartments and other tenant services; and Mixed-use, which include rental of retail space and other tenant services.

Amicus Therapeutics is a biotechnology company focused on the discovering, developing, and delivering medicines for diseases. The company's Commercial Product and Product Candidates include Galafold? (Migalastat HCl), which is for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; Enzyme Replacement Therapy for Pompe disease; and Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder, which is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development.

Berkshire Hills Bancorp is the holding company for Berkshire Bank and Berkshire Insurance Group, Inc. The company provides a range of deposit, lending, insurance, and wealth management products to retail and commercial customers. The company's loan portfolio is segregated into the following segments: commercial real estate, commercial and industrial, residential mortgage, and consumer. Commercial real estate loans include construction, single and multi-family, and other commercial real estate classes. Residential mortgage loans include classes for one-to-four family owner occupied and construction loans. Consumer loans include home equity, direct and indirect auto, and other consumer loan classes.

Deciphera Pharmaceuticals is a biopharmaceutical company. The company is engaged in commercial preparations to support the potential Untied States launch of ripretinib for the treatment of patients with gastrointestinal stromal tumors (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib. In addition, the company is studying ripretinib in its global pivotal Phase 3 study, INTRIGUE, in second-line GIST patients, comparing ripretinib to sunitinib. The company is developing other clinical-stage drug candidates, DCC-3014 and rebastinib, which target the macrophage tumor microenvironment. Additionally, the company is conducting preclinical investigational new drug-enabling studies with DCC-3116.

Emclaire Financial is a financial holding company. The company provides a range of retail and commercial financial products and services to customers in western Pennsylvania through its wholly owned subsidiary bank, The Farmers National Bank of Emlenton (the Bank). The company also provides real estate settlement services through its subsidiary, Emclaire Settlement Services, LLC. The Bank's principal business consists of accepting deposits from the general public and investing such funds in real estate loans secured by liens on residential and commercial property, consumer loans, commercial business loans, marketable securities and interest-earning deposits.

Horizon Technology Finance is a finance company that lends to and invests in development-stage companies in the technology, life science, healthcare information and services and cleantech industries (collectively, Target Industries). The company focuses on making secured debt investments to venture capital backed companies in its Target Industries. The company is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company. The company also has elected to be treated as a regulated investment company. The company's investment activities, and its day-to-day operations, are managed by its advisor, Horizon Technology Finance Management LLC.

Keurig Dr Pepper is a beverage company with a portfolio of flavored (non-cola) carbonated soft drinks (CSDs), non-carbonated beverages, and is a producer of single serve brewing systems. The company's Coffee Systems segment develops and sells a variety of Keurig brewers, brewer accessories and other coffee-related equipment. The company's Packaged Beverages segment manufactures and distributes packaged beverages of its brands. The company's Beverage Concentrates segment manufactures and sells beverage concentrates. The company's Latin America Beverages segment participates mainly in the carbonated mineral water, flavored CSD, bottled water and vegetable juice categories.

Opko Health is a healthcare company. The company manages two segments: Diagnostics, which provides laboratory testing services utilized by healthcare providers in the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health and correctional healthcare; and Pharmaceutical, which includes Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease (CKD) and vitamin D insufficiency, and Alpharen (Fermagate Tablets) for the treatment of hyperphosphatemia in CKD patients requiring regular hemodialysis.

Penns Woods Bancorp is a bank holding company. Through its subsidiaries, Jersey Shore State Bank (JSSB) and Luzerne Bank (collectively, the Banks), the company is engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. The Banks provide insurance, securities brokerage services, annuity and mutual fund investment products, and financial planning through JSSB's subsidiary, The M Group, Inc. Services provided by the Banks include accepting time, demand and savings deposits including Super NOW accounts, money market accounts, and fixed rate certificates of deposit.

Phreesia is a provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. Through the SaaS-based Phreesia Platform (the "Phreesia Platform"), the company offers healthcare provider organizations a robust suite of solutions to manage the patient intake process and an integrated payments solution for secure processing of patient payments. The company's Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients.

Sumo Group is engaged in the development of video games providing both turnkey and co-development solutions. Co.'s development solution, includes initial concept and pre-production, production and development, and post-release support. Co. develops games across all console platforms, PC, handheld and mobile devices.